Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Zura Bio ( (ZURA) ).
Zura Bio Limited, a clinical-stage immunology company, is set to engage with investors at two major conferences in November 2024. The company, known for developing dual-pathway antibodies for autoimmune diseases, will participate in the Guggenheim Healthcare Innovation Conference in Boston and the Jefferies London Healthcare Conference. These events provide a platform for Zura Bio to showcase its promising therapeutic developments, including tibulizumab, crebankitug, and torudokimab, which are poised for Phase 2 trials.
For detailed information about ZURA stock, go to TipRanks’ Stock Analysis page.
